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Abstract. In this paper we describe a demonstration of an innovative B2B infrastructure which 
can  be  used  to  support  collaborations  in  the  pharmaceutical  industry  to  achieve  the  drug 
discovery goal.  Based on experience gained in a wide range of collaborative projects in the 
areas of grid technology, semantics and data management we show future work and new topics 
in B2B infrastructures which arise when considering the use of patient records in the process of 
drug discovery and in healthcare applications. 
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Introduction 
In  the  last  decades,  advances  in  the  life  science  sector  have  facilitated  the  rapid 
acquisition of vast amounts of data in a multitude of projects, which today leads to a 
huge number of distributed databases and analysis methods [1]. The data is used by the 
life science community for various in-silico experiments that are by their very nature, 
hypothesis driven, ad-hoc and highly specialised to the problem with which they are 
associated.  For  example,  in  medicine,  sequences  provide  a  basis  for  the  study  of 
susceptibility  to  disease  and  the  development  of  new  preventative  and  therapeutic 
approaches, whereas, in cell biology, the interactions between components of cellular 
circuitry can be studied. 
In  the  pharmaceutical  industry  many  additional  challenges  are  faced  in  the 
development of new drug products. Drug discovery is a complex high risk process with 
many development phases involving people from various disciplines accessing rich and 
diverse information sources under the constraints of external factors such as regulations 
and strong competition. The drug discovery process, in general referred to as a pipeline, 
includes several distinct phases from the generic research through to clinical trials, 
project  lifecycle  management  and  hopefully  the  final  drug  product.  Pharmaceutical 
companies  are  faced  with  the  challenge  of  how  to  adopt  new  approaches  and 
technologies for the distribution, integration, discovery, visualisation, annotation and 
validation of information in order to provide decision makers with accurate information 
and  help  to  reduce  companies’  costs  and  risks  whilst  increasing  the  probability  of 
successfully designing and developing a new drug.  
The  EU  IST  SIMDAT  Project  [2]  is  deploying  Grid  technology  to  support  new 
business  models  for carrying out bioinformatics research  within the drug discovery 
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innovation.soton.ac.uk pipeline. Innovative solutions to assist this pipeline exist in large pharmaceutical and 
biotechnology companies as well as in academic institutions. Increasingly, it is the use 
of  B2B  infrastructure  technology  to  enable  successful  partnerships  within  the 
pharmaceuticals business that will help achieve the drug discovery goal. 
In  this  paper,  we  show  how  an  innovative  B2B  infrastructure  drawn  from  the 
SIMDAT’s Grid solution portfolio can be used to support B2B collaborations in the 
pharmaceutical  industry  to  achieve  the  drug  discovery  goal  (section  1).  The 
demonstration  will  include  workflows,  distributed  data  access  techniques,  semantic 
web and several Grid infrastructure components. We further discuss new challenges for 
future B2B infrastructures arising when including patient data in the process of drug 
discovery and personalised healthcare (section 2). 
1. Demonstrating B2B infrastructures for the pharmaceutical industry 
The focus of our demonstration is based on a scenario drawn from the SIMDAT project 
using  bioinformatics  in  the  collaborative  development  of  new  drugs  through  Grid-
enabled partnerships during the target identification phase of the pipeline. This scenario 
shows  the  potential  of  business-to-business  (B2B)  and  business-to-academic  (B2A) 
collaborations within the pharmaceutical industry. In the specific business case, we will 
demonstrate how a B2B infrastructure can support drug discovery partnerships between 
big  pharmaceutical  (GlaxoSmithKline)  and  SME  biotechnology  suppliers 
(Inpharmatica)  in  the  analysis  and  annotation  of  selected  sets  of  proteins.  The 
demonstration scenario comprises the following elements: 
 
1.  Inpharmatica publishes a service to provide aggregate and detailed annotation 
of  protein  data  including  similarity  based  on  structure,  ligand  binding  sites  and 
sequence annotation in various predetermined formats.  
2.  GlaxoSmithKline subscribes to, and requests results using the service. 
3.  Each  request  for  the  Grid  services  identifies  a  set  of  data  that  requires 
additional annotation and the required format for the resulting annotation. 
4.  Inpharmatica delivers the resulting annotation to complete the transaction. 
  
Fig. 1: Managing B2B collaborations 
While this scenario is typical for collaborations in the pharmaceutical sector, it also 
unveils requirements for the underlying B2B infrastructure supporting cost effective 
dynamic  collaborations.  This  includes  business  relationship  management,  minimal 
authorisation and administration efforts, explicit trust decision points, and industrial 
operational  security  policies  (ISO/IEC  17799:2005).  Dynamic  collaborations  allow 
organizations to participate in distributed and managed scientific processes whilst still 
enforcing commercial level security policies for the protection of intellectual property 
rights and business objectives. Figure 1 illustrates the workflow of establishing and 
managing B2B collaborations. These collaborations are underpinned by the GRIA B2B 
infrastructure [3], a secure and interoperable Open-Source Grid middleware. We will 
demonstrate how the infrastructure supports the following more general requirements 
for B2B collaboration.  
Dynamic Trust and Security   
Trust  and  Security  are  major  issues  in  establishing  business  relationships  between 
companies  in  the  drug  discovery  pipeline.  In  GRIA  we  have  developed  security 
mechanisms based on Service-Oriented Architecture (SOA). GRIA has dynamic policy 
management features to define and enforce policies for accessing service and consumer 
management  functions,  and  for  each  individual  data  item  and  computation.    This 
dynamic  policy  feature  enables  users  to  orchestrate  interactions  between  services 
operated  by  totally  independent  providers,  and  to  share  results  with  other  users  as 
required. The GRIA 5 consumer management package also supports integration with 
'home site' user authentication, and service policies can specify which site(s) are trusted 
to authenticate users against each individual policy clause. This makes it very easy to 
set up business relationships and start providing services to new customers within a few 
minutes. 
 
On top of these security mechanisms we demonstrate an End-to-End (E2E) Security 
framework developed by NEC [6]. E2E Security supports the provisioning of security 
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M Ma an na ag ge er r   services, including encryption, integrity protection, and authentication, from end-to-end 
even in the presence of intermediate systems like proxies or message queuing systems. 
Service Level Agreements and Quality of Service 
In B2B collaborations, service providers and customers trade resources (applications, 
data,  processing,  storage)  under  the  terms  of  bilateral  Service  Level  Agreements 
(SLAs). An SLA describes quality of service (QoS) and are used as contracts between 
service providers and service consumers (customers), working out risks (in terms of 
costs) to providers and working out value (i.e. price) to customers. An SLA gives a 
promise to provide services, for instance to initiate a specific processing step on protein 
data. We will demonstrate how to create and negotiate SLAs to regulate the use of 
resources in our business scenario. 
Usage Control and Accounting 
Service providers deploy application services appropriate to their business operation.  
These  services  generate  usage  reports  using  their  own  QoS  criteria  which  may  be 
qualitative (e.g. error conditions) or quantitative (e.g. processing time, data transferred). 
The  metrics  are  flexible  and  depending  upon  the  application  could  be  CPU  time, 
number  of  active  application  licenses,  data  storage,  number  of  submitted  jobs,  etc.  
GRIA uses these reports to monitor customer usage and the level of commitments from 
existing agreements compared with available capacity. A specific management service 
records and constrains the customer usage against the service provider capacity and the 
terms of agreedSLAs.  
  
Fig 2: Usage report showing number of CPU seconds 
 
Adaptive Workflows 
Defining  and  enacting  distributed  workflows  is  one  of  the  key  drivers  for  grid 
computing and Service-Oriented Architectures. In our demonstration we use Taverna 
[4]  or  InforSense  KDE  [5]  to  construct  and  enact  the  workflow  required  for  our 
business case. We will also show how novel service discovery and service registries 
can be used to adapt workflows on the fly to fulfil business requirements. An adaptive 
workflow  is  not  fixed  to  specific  service  instances  but  rather  discovers  and  selects 
services based on business constraints, which could be described for instance by SLAs 
and current usage.. 
2. From bioinformatics to healthcare: Issues for future B2B infrastructures 
 
A  great  deal  of  experience  has  been  gained  from  work  in  GRID,  SOA  and  data 
management projects, both in the health-care sector and others.  This experience has 
highlighted many of the issues that arise when dealing with the management of health-
care records and the handling of personal data.  A range of techniques, such as those of 
data fusion (SANY), media and knowledge handling (ARTEMIS, E-CHASE), secure 
middleware (GEMSS, GRIA, SIMDAT, NEXTGRID), creation of ontologies (GEMSS, 
ARTEMIS)  and  handling  of  heterogeneous  data  sources  (E-CHASE,  SANY)  are 
common  across  many  disciplines.    As  an  integrated  bioinformatics  and  healthcare 
environment develops, so these areas of expertise will need to be brought to bear on the 
solution of fundamental challenges which arise. 
 The following brief discussion gives some specific examples of the new challenges 
being faced in the developing healthcare environment:  
 
•  Data Fusion 
Data is being created from a wide variety of sources and sensors, and as citizens 
start to live in a world increasingly populated with ubiquitous sensors monitoring 
their  lifestyles  and  biometrics,  so  there  will  be  an  increasing  need  to  fuse 
heterogeneous data, interpolate and predict data, use and apply models to extract 
knowledge  about  the  health  of  individuals  and  populations,  and  to  predict,  for 
example, epidemiological developments. 
•  Heterogeneous data sources 
The collection of data is from a huge variety of sources, which can be historical 
data held in databases through to live measurements such as blood-pressure and 
temperature or media based records of x-ray or scanner results.  Additionally, this 
data may be stored or delivered using one of a number of protocols or formats, 
with different structures or ontologies to support them.  Future healthcare systems 
will need to be able to handle and integrate this wide variety of data. 
•  Management of data sources (patient information, images and media) 
Health data is increasingly coming from a wide variety of sources, and this range 
will increase in the future.  Image data (such as scans, digitised X-rays, in-vitro 
video monitoring) are created, stored and delivered in different formats and with 
markedly  different  levels  of  descriptive  metadata.    Future  healthcare  data 
management will need to take account of these different formats, and manage the 
creation of metadata so as to improve the ability of data systems to search and 
retrieve  relevant  information.    Global  ontologies  will  be  essential  to  allow 
healthcare professionals from a range of disciplines to access all the data relevant 
to their needs. 
•  Integrated middleware 
Building on the experience gained by implementers in academic, scientific and 
business  applications  of  distributed  computing  and  grid-based  systems,  the 
particular needs of future healthcare systems can be addressed in a holistic fashion 
to ensure that interoperability, security, managed exchange of data and integration 
of dynamic acquired information (such as personal health monitoring systems) is 
built-in  from  the  ground  up.    Service  oriented  architectures  (SOA)  and 
infrastructures (SOI) will need to be developed in which workflows connect all the 
functional components seamlessly, whilst maintaining data integrity and ease of 
use for the healthcare professional. 
•  Personal monitoring and reporting Future healthcare systems will encompass preventative medicine based on personal 
monitoring systems.  Intelligent systems are needed which will correlate data and 
patient history, and create alerts and warnings based on data fusion and modelling 
techniques. 
•  Security and protected access to data 
There are a number of levels of security and trust raised in the healthcare scenario, 
which are similar to those approached in other situations.  Privacy issues arise in 
the  use,  sharing  and  access  of  health  records,  some  of  which  are  currently 
controlled  by  legislation  which  is  often  different  in  different  countries.  Health 
records  maintained  by  different  agencies  or  local  bodies  will  often  be  held  on 
incompatible  systems, and  may  well be subject to differing local, national and 
international legislation, as well as personal preferences expressed by the person to 
whom the data relates.  The means to manage these many levels of security and 
access  need  to  be  incorporated  into  future  integrated  healthcare  systems,  and 
cannot be implemented as an add-on function. 
•  Virtual Physiological Human 
Creation of the Virtual Physiological Human (VPH) is an opportunity to integrate 
what are currently localised models of physiological functions into an increasingly 
complex model.  As this model becomes more complete, so it will provide the 
opportunity for achieving an ever-wider range of functions:- 
-  from nano to macro 
investigation  of  behaviour  at  the  molecular  level,  the  cellular  level,  the 
organism level and the level of populations 
-  in-silico drug efficacy 
integrated studies of drug function and biological impact 
-  training 
virtual  training  of  physicians  and  other  healthcare  workers  on  accurate 
simulations of the physiology of patients 
-  integrated physiological models 
comprehensive modelling of the interactions between physiological processes 
3. Conclusion 
In this paper we describe a demonstration based upon a real situation that has been 
investigated in the European SIMDAT project.  The role of users in the pharmaceutical 
sector  is  crucial  in  identifying  the  needs  of  the  business-to-business  (B2B)  and 
business-to-academic (B2A) communities.  The demonstration shows the potential of 
distributed workflows in grid computing and service oriented architectures in fulfilling 
those needs.  Vital elements, such as metrics and Service Level Agreements are shown 
operating as an integral part of that workflow.  The dynamic collaborations which are 
formed  are  supported  by  minimal  administration  requirements,  yet  provided  with 
industrial-strength  security  policies,  allowing  high  levels  of  trust  to  be  maintained between collaborating entities.  It is also shown that SLA based business partnerships 
can allow quality of service to be managed effectively. 
We conclude with a discussion of the future requirements of distributed workflows in 
the  healthcare  sector,  taking  into  account  the  future  needs  of  ubiquitous  sensors, 
integrated healthcare provision and the need for maintaining security and privacy.  The 
future needs of implementing the ambitions Virtual Physiological Human project are 
also briefly discussed.  Based on work performed in related grid-based projects it is 
shown that there is much original work still to be done, but that it can be seen in the 
context of a continuation of knowledge and expertise gained through the application of 
grid architecture and SOA’s to practical, user driven scenarios. 
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